The effect of selective estrogen receptor modulators on parameters of the hypothalamic-pituitary-gonadal axis.
The SERMs currently in clinical practice or in late stages of clinical development have been studied primarily for their effects on the breast, cardiovascular, bone, and reproductive systems. The effect of SERMs on the hypothalamic-pituitary-gonadal (HPG) axis has not been the primary focus of the studies conducted thus far. However the effect of SERMs on the HPG axis and the associated regulation of endocrine parameters may play an important role in their overall clinical profile. In this review the effects of selected SERMs on the HPG axis in premenopausal women, postmenopausal women, and men are summarized.
Plouffe
L
L
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46284, USA. lplouffe@lilly.com
Siddhanti
S
S
D005260:Female; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D006066:Gonads / Q000187:drug effects*; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects*; D008297:Male; D017698:Postmenopause / Q000187:drug effects / Q000502:physiology; D017697:Premenopause / Q000187:drug effects / Q000502:physiology; D020845:Selective Estrogen Receptor Modulators / Q000494:pharmacology*
D020845:Selective Estrogen Receptor Modulators; D005640:Follicle Stimulating Hormone